MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin beta2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research[1][2].
Target:
Integrin
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
